Pacira Pharmaceuticals (PCRX) PT Lowered to $57 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Canaccord Genuity Downgrades Pacira Pharmaceuticals (PCRX) to Hold
October 30, 2017 2:20 AM EDTCanaccord Genuity downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $33.00 (from $44.00).
Analyst Dewey Steadman says the IMS continues to disappoint and therefore steps to the sidelines noting he expects share price pressures following guidance and efforts by... More
